Totipotent

Multipotent stem cells have the ability to develop specific types of cells (terminally differentiated cells). For example a blood stem cell (multipotent) can develop into a red blood cell, white blood cell or platelets (all specialized cells).

Human adipose tissue is a source of multipotent stem cells.

For example, multipotent adult stem cells in bone marrow, or hematopoietic stem cells, can give rise to all blood cell types, and neural stem cells in the brain can give rise to glial and neuronal cells.

Totipotency has the highest differentiation potential and allows cells to form both embryo and extra-embryonic structures. One example of a totipotent cell is a zygote, which is formed after a sperm fertilizes an egg. These cells can later develop either into any of the three germ layers or form a placenta.

The major difference between embryonic and somatic stem cells is that embryonic stem cells have the potential to differentiate into all cell types of the body, as they are pluripotent stem cells (cells that are able to differentiate into three primary germ cell layers of the early embryo and, thus, into any cell type …

Cons of STEM Education:

• No clear-cut guidelines or standards. The biggest issue with STEM education is that there are no set guidelines for what students should be learning or how qualified the teachers need to be.
• Starts too late in life.
• Under-performing students can get left out.

Some opponents of stem cell research argue that it offends human dignity or harms or destroys human life. Laboratory research on adult stem cells is generally uncontroversial. Research with human subjects becomes controversial because some experimental “therapies” could harm patients.

However, human embryonic stem cell (hESC) research is ethically and politically controversial because it involves the destruction of human embryos. In the United States, the question of when human life begins has been highly controversial and closely linked to debates over abortion.

The US

Transplant costs (mean $22,032) and follow-up costs (mean $22,686) each accounted for approximately 15% of the total costs. Conclusion: ASCTs are costly procedures with mean payer costs of almost $150,000. This study reviewed recent U.S. managed care health plan claims data to determine the component costs of ASCT.